Ironwood Pharmaceuticals Initiates Phase 2 Clinical Study Of IW-3718 In Refractory Gastroesophageal Reflux Disease
Published: Mar 18, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in its Phase IIa clinical study of its investigational compound IW-3718 in patients suffering from gastroesophageal reflux disease (GERD) who have not responded adequately to treatment with a proton pump inhibitor (PPI). Data are expected in the first half of 2015.
Help employers find you! Check out all the jobs and post your resume.